SOURCE Agilent Systems Inc.. Agilent Technologies announces brand-new multiplexing capability in SureSelect Target Enrichment System Agilent Technologies Inc. today announced that its Agilent SureSelect Target Enrichment System supports multiplexed DNA sequencing of 12 to 16 samples per lane based on the next-generation sequencing platform, reducing costs and increasing throughput up to 16-fold.D., Agilent marketing manager, Emerging Genomic Applications. The kits are optimized for the Illumina Genome Analyzer and the Applied Biosystems SOLiD platform. The Illumina can sequence 12 samples per lane for a total of 96 samples per run. The Good platform can sequence 16 samples per quadrant or octet, allowing up to 256 samples to be processed per run.All sufferers shall undergo a DTI mind scan and provide blood samples. Researchers expect to screen about 15,000 proteins from the blood samples, and search for the small number of proteins that will vary among the head injury group. Further analysis includes a scholarly study of the serum markers seven days and one month following the head injury, to determine how cells transformation as the mind heals, Bazarian stated.S. Soldiers and public protection officers. Development of a rapid blood test can be an essential first rung on the ladder to creating a treatment. Previous NIH funding allowed him to start the nation’s first Emergency Department-based traumatic brain injury registry, to understand how and where most people get injured.